INNATE PHARMA : preclinical data opening new perspectives for development of
Lirilumab in combination to be presented at ASH
oEvidence for lirilumab single-agent activity in lymphoma
oDemonstration of enhanced efficacy of anti-CD20 antibodies when combined
oTo be presented at ASH meeting, December 9, abstract available online now
MARSEILLE, France, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the
"Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company
developing first-in-class drug candidates for cancer and inflammatory
diseases, announces that a new set of preclinical data on lirilumab will be
presented in a poster at the upcoming 55th ASH Annual Meeting (December 7-10,
2013) in New Orleans, LA:
"Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer
Cells As Monotherapy and In Combination With Anti-CD20 Antibodies"
Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents:
Date:Monday, December 9, 2013
Presentation Time: 6:00 PM - 8:00 PM
Location: Ernest N. Morial Convention Center, Hall G
The abstract is available on the meeting website.
Lirilumab is a natural killer (NK) cell checkpoint inhibitor undergoing
clinical development with partner Bristol-Myers Squibb in Acute Myeloid
Leukemia in monotherapy and in combination settings in solid tumors. The new
preclinical results are from research conducted by Dr Holbrook Kohrt from
Stanford University, Innate Pharma and CIML^1. They support the monotherapy
activity of lirilumab in mouse models of lymphoma, through the enhancement of
NK cell cytotoxicity. Furthermore, the new data showed that in combination
with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated,
antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and
in vivo in mouse models. Taken together, these data reinforce the rationale
for the development of lirilumab in onco-hematology, and open new perspectives
for the combination of lirilumab with antibody drugs active through ADCC.
Nicolai Wagtmann, CSO of Innate Pharma, said: "What is particularly exciting
and impressive about these new preclinical results is that we show that
lirilumab, beyond single-agent activity, also enhanced the efficacy of
rituximab in vivo through ADCC. These results raise the possibility that
lirilumab may similarly enhance the ADCC-activity of other therapeutic
antibodies currently marketed or in clinical development in cancer and other
About lirilumab (IPH2102/BMS-986015):
Lirilumab is a fully human monoclonal antibody blocking interaction between
Killer-cell immunoglobulin-like receptors (KIR) on NK cells with their
ligands. Blocking these receptors facilitates activation of NK cells and,
potentially, destruction of tumor cells by the latter.
Lirilumab is licensed to Bristol-Myers Squibb Company (NYSE:BMY) by Innate
Pharma. As part of the license agreement, Bristol-Myers Squibb holds exclusive
worldwide rights to develop, manufacture and commercialize lirilumab and
related compounds blocking KIR receptors, for all indications. Under the
agreement, Innate Pharma conducts the development of lirilumab through Phase
II in AML.
Lirilumab is currently tested in a randomized, double-blind,
placebo-controlled Phase II trial in elderly patients with AML in a
maintenance setting. In addition, two phase I trials are ongoing in solid
tumors, testing lirilumab in combination-therapy with ipilimumab (anti-CTLA4)
and nivolumab (anti-PD-1, BMS-936558), respectively.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drug candidates for cancer and inflammatory diseases.
The Company specializes in the development of novel monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 84 employees as at September
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code FR0010331421
Ticker code IPH
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.
For additional information, please contact:
Innate Pharma ATCG Press
Laure-Hélène Mercier Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53
1Center of Immunology - Marseille Luminy
*Rituximab is a therapeutic antibody approved for the treatment of
non-Hodgkin's lymphoma and rheumatoid arthritis.
Press Release: http://hugin.info/155662/R/1743146/586252.pdf
Press spacebar to pause and continue. Press esc to stop.